Kodiak Sciences (KOD)
(Delayed Data from NSDQ)
$2.55 USD
-0.07 (-2.67%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $2.56 +0.01 (0.39%) 6:12 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Company Summary
Palo Alto, CA-based Kodiak Sciences Inc., is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, which are the major causes of blindness. The company’s proprietary antibody biopolymer conjugate (ABC) platform is designed to maintain potent and effective drug levels in ocular tissues for longer periods than the currently marketed biologic medicines for treating retinal diseases.
Founded in 2009, Kodiak Sciences currently has no marketed drug in its portfolio.
In late 2023, Kodiak Sciences decided to reboot its tarcocimab development program after witnessing positive top-line results from its phase ...
Company Summary
Palo Alto, CA-based Kodiak Sciences Inc., is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics to treat chronic, high-prevalence retinal diseases, which are the major causes of blindness. The company’s proprietary antibody biopolymer conjugate (ABC) platform is designed to maintain potent and effective drug levels in ocular tissues for longer periods than the currently marketed biologic medicines for treating retinal diseases.
Founded in 2009, Kodiak Sciences currently has no marketed drug in its portfolio.
In late 2023, Kodiak Sciences decided to reboot its tarcocimab development program after witnessing positive top-line results from its phase III GLOW study evaluating the same in moderately severe to severe non-proliferative diabetic retinopathy (NPDR). The positive data readouts from DAYLIGHT, BEACON and GLOW studies give the company three successful phase III pivotal studies with tarcocimab tedromer across three different retinal vascular and exudative diseases, such as wet age-related macular degeneration (wet AMD), retinal vein occlusion (RVO) and NPDR.
Kodiak Sciences believes that it requires one additional pivotal study to support a regulatory filing of tarcocimab for all three indications, such as wet AMD, RVO and NPDR.
The company had earlier faced a major developmental setback which led to the abandonment of the development program of its lead candidate, tarcocimab, in the treatment of retinal vascular diseases. The late-stage GLEAM and GLIMMER studies could not meet the primary efficacy endpoints of showing non-inferior visual acuity gains for tarcocimab dosed every eight to 24 weeks compared with aflibercept given every eight weeks in the treatment of DME. Additionally, an unexpected increase in cataracts was observed over time in the tarcocimab arms of both studies.
Kodiak’s second pipeline candidate, KSI-501, is an anti-IL6 and anti-VEGF bispecific biopolymer conjugate. It is expected to advance into pivotal studies in 2024 for retinal vascular diseases featuring an inflammatory component.
Kodiak is also currently evaluating a third investigational medicine, KSI-101, an unconjugated protein portion of KSI-501 and is a novel bispecific protein targeting IL-6 and VEGF, which offers a different therapeutic approach. It is currently being developed for retinal inflammatory conditions.
General Information
Kodiak Sciences Inc
1200 PAGE MILL ROAD
PALO ALTO, CA 94304
Phone: 650-281-0850
Fax: NA
Email: ir@kodiak.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 8/12/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.87 |
Current Year EPS Consensus Estimate | -3.55 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 8/12/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 2.62 |
52 Week High | 7.77 |
52 Week Low | 1.37 |
Beta | 2.38 |
20 Day Moving Average | 229,954.59 |
Target Price Consensus | 3.50 |
4 Week | -19.14 |
12 Week | -18.38 |
YTD | -13.82 |
4 Week | -15.67 |
12 Week | -20.08 |
YTD | -24.36 |
Shares Outstanding (millions) | 52.53 |
Market Capitalization (millions) | 137.64 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 39.26% |
vs. Previous Quarter | 27.43% |
vs. Previous Year | NA% |
vs. Previous Quarter | NA% |
Price/Book | 0.57 |
Price/Cash Flow | NA |
Price / Sales | NA |
6/30/24 | Pending Next EPS Report |
3/31/24 | -81.11 |
12/31/23 | -80.20 |
6/30/24 | Pending Next EPS Report |
3/31/24 | -45.38 |
12/31/23 | -46.17 |
6/30/24 | Pending Next EPS Report |
3/31/24 | 10.12 |
12/31/23 | 6.93 |
6/30/24 | Pending Next EPS Report |
3/31/24 | 10.12 |
12/31/23 | 6.93 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | Pending Next EPS Report |
3/31/24 | 4.59 |
12/31/23 | 5.07 |
6/30/24 | NA |
3/31/24 | NA |
12/31/23 | NA |
6/30/24 | Pending Next EPS Report |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | Pending Next EPS Report |
3/31/24 | 0.00 |
12/31/23 | 0.00 |